Evidence map›Paper›PMID 29755116›Full record

ArticleBritish journal of cancer2018

Health-related quality of life after treatment for bladder cancer in England.

Samantha J Mason, Amy Downing, Penny Wright, Luke Hounsome, Sarah E Bottomley, Jessica Corner, Mike Richards, James W Catto, Adam W Glaser

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 3 pooled it
8.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 3 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. The current use of the EORTC QLQ-NMIBC24 and QLQ-BLM30 questionnaires for the assessment of health-related quality of life in bladder cancer patients: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Samantha J MasonLeeds Institute of Cancer and Pathology, University of Leeds, Level 11, Worsley Building, Clarendon Way, Leeds, LS2 9NL, UK. s.j.mason@leeds.ac.uk.
Amy DowningLeeds Institute of Cancer and Pathology, University of Leeds, Level 11, Worsley Building, Clarendon Way, Leeds, LS2 9NL, UK.
Penny WrightLeeds Institute of Cancer and Pathology, University of Leeds, Level 11, Worsley Building, Clarendon Way, Leeds, LS2 9NL, UK.
Luke HounsomePublic Health England, 2 Rivergate, Temple Quay, Bristol, BS1 6EH, UK.ORCID http://orcid.org/0000-0001-5231-1394
Sarah E BottomleyAcademic Urology Unit, University of Sheffield, The Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
Jessica CornerExecutive Office, University of Nottingham, Trent Building, University Park, Nottingham, NG7 2RD, UK.
Mike Richards, London, UK.
James W CattoAcademic Urology Unit, University of Sheffield, The Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
Adam W GlaserLeeds Institute of Cancer and Pathology, University of Leeds, Level 11, Worsley Building, Clarendon Way, Leeds, LS2 9NL, UK.
University of Leeds · GBUniversity of Sheffield · GBPublic Health England · GBUniversity of Nottingham · GB

Funding

Department of Health
6 · The paper itself

Abstract

backgroundLittle is known about quality of life after bladder cancer treatment. This common cancer is managed using treatments that can affect urinary, sexual and bowel function.

methodsTo understand quality of life and inform future care, the Department of Health (England) surveyed adults surviving bladder cancer 1-5 years after diagnosis. Questions related to disease status, co-existing conditions, generic health (EQ-5D), cancer-generic (Social Difficulties Inventory) and cancer-specific outcomes (Functional Assessment of Cancer Therapy-Bladder).

resultsIn total, 673 (54%) patients responded; including 500 (74%) men and 539 (80%) with co-existing conditions. Most respondents received endoscopic treatment (60%), while 92 (14%) and 99 (15%) received radical cystectomy or radiotherapy, respectively. Questionnaire completion rates varied (51-97%). Treatment groups reported ≥1 problem using EQ-5D generic domains (59-74%). Usual activities was the most common concern. Urinary frequency was common after endoscopy (34-37%) and radiotherapy (44-50%). Certain populations were more likely to report generic, cancer-generic and cancer-specific problems; notably those with co-existing long-term conditions and those treated with radiotherapy.

conclusionThe study demonstrates the importance of assessing patient-reported outcomes in this population. There is a need for larger, more in-depth studies to fully understand the challenges patients with bladder cancer face.

Indexed as

Patient Reported Outcome MeasuresAdultAgedAged, 80 and overComorbidityCystectomyEndoscopyEnglandFemaleHumansMaleMiddle AgedQuality of LifeRadiotherapySurveys and QuestionnairesUrinary Bladder Neoplasms

Identifiers

PMID29755116
PMCPMC5988662
OpenAlexW2802532839

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.